Servier will acquire Day One Biopharmaceuticals in a $2.5 billion deal to strengthen its rare oncology portfolio and advance targeted therapies, including programs for pediatric low-grade glioma.
Written By: Nikita Jha, BPharm
Reviewed By: Pharmacally Editorial Team
Servier has entered into a definitive agreement to acquire Day One Biopharmaceuticals in an all-cash transaction valued at approximately $2.5 billion, a move aimed at strengthening its rare oncology portfolio and accelerating development of targeted cancer therapies.
The acquisition will integrate Day One’s oncology programs with Servier’s global development and commercialization capabilities, expanding its pipeline across both pediatric and adult cancers with significant unmet medical needs.
The transaction is expected to position Servier as a leading player in pediatric low-grade glioma, a rare brain tumor that primarily affects children and remains an area with limited targeted treatment options.
Day One has focused its research strategy on precision oncology therapies designed to address life-threatening cancers, particularly in pediatric populations where drug development has historically lagged behind adult oncology.
By combining Day One’s scientific expertise in targeted oncology drug development with Servier’s global infrastructure and experience in rare cancers, the companies aim to accelerate the development and potential commercialization of new therapies for patients with high unmet medical needs.
The deal also broadens Servier’s oncology pipeline with programs ranging from early-stage research through late-stage clinical development, supporting its long-term strategy to expand innovation in rare and difficult-to-treat cancers.
Servier expects the transaction to close in the second quarter of 2026, subject to customary regulatory and closing conditions.
Servier President Olivier Laureau said the acquisition strengthens the company’s position in rare oncology and supports its long-term strategy to advance innovative treatments for patients with rare cancers, aligning with Servier’s 2030 ambition.
Jeremy Bender, PhD, CEO of Day One Biopharmaceuticals, said Servier’s expertise in rare cancers and targeted therapies makes it a strong partner to advance Day One’s portfolio, particularly its lead program for pediatric low-grade glioma, while continuing its patient-focused mission in oncology.
Headquartered in France, Servier is an international pharmaceutical group focused on advancing innovative treatments in oncology, neurology, and cardiometabolic diseases, with medicines distributed in more than 130 countries and nearly 20% of its brand-name revenue invested in research and development.
Day One Biopharmaceuticals, based in Brisbane, California, is a commercial-stage biotechnology company focused on developing targeted therapies for life-threatening cancers, with a particular emphasis on pediatric oncology and precision treatments for tumors with significant unmet medical needs.
Reference
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio, 06 March 2026, https://servier.com/wp-content/uploads/2026/03/servier-day-one-biopharmaceuticals_PR.pdf
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio, 06 March 2026, https://ir.dayonebio.com/news-releases/news-release-details/servier-and-day-one-biopharmaceuticals-announce-acquisition
About Writer
Nikita Jha BPharm
She is a pharmacy graduate with expertise in clinical research, pharmacovigilance, and medical writing. In her words, she is passionate about translating complex scientific data into clear, accurate healthcare communications that advance drug safety and patient care.